Free Trial

Matthew O'Brien Analyst Performance

Analyst at Piper Sandler

Matthew O'Brien is a stock analyst at Piper Sandler in the medical sector, covering 24 publicly traded companies. Over the past year, Matthew O'Brien has issued 1 stock ratings, including and buy recommendations. While full access to Matthew O'Brien's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Matthew O'Brien's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
65 Last 10 Years
Buy Recommendations
81.67% 49 Buy Ratings
Companies Covered
24 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy81.7%49 ratings
Hold18.3%11 ratings
Sell0.0%0 ratings

Out of 60 total stock ratings issued by Matthew O'Brien at Piper Sandler, the majority (81.7%) have been Buy recommendations, followed by 18.3% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
66.7% of companies on NASDAQ
16 companies
NYSE
33.3% of companies on NYSE
8 companies

Matthew O'Brien, an analyst at Piper Sandler, currently covers 24 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
24 companies
100.0%

Matthew O'Brien of Piper Sandler specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED INSTRUMENTS
11 companies
45.8%
MED PRODUCTS
7 companies
29.2%
MED/DENTAL - SUPP
4 companies
16.7%
MEDICAL INFO SYS
1 company
4.2%
MED - BIOMED/GENE
1 company
4.2%

Matthew O'Brien's Ratings History at Piper Sandler

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
10/31/2025Reiterated Rating$19.12$25.00Overweight